81854-56-0

Basic information

• Product Name: N,N-DI-N-PROPYL-L-ALANINE
• Synonyms: N,N-DI-N-PROPYL-L-ALANINE;N,N-DI-N-PROPYL-L-ALA-OH;Dipropylalanine;(S)-(+)-N,N-Dipropylalanine, (S)-(+)-N,N-Dipropylalanine;N,N-Dipropylalanine;N,N-Dipropyl-L-alanine;(S)-(+)-N,N-DIPROPYLALANINE;N,N-DIPROPYL-L-ALANINE
• CAS NO: 81854-56-0
• Molecular Formula: C9H19NO2
• Molecular Weight: 173.25
• Mol File: 81854-56-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 94-95 °C(lit.)
• Boiling Point: 253.8°C at 760 mmHg
• Flash Point: 107.3°C
• Appearance: /
• Density: 0.965g/cm³
• Vapor Pressure: 0.00554mmHg at 25°C
• Refractive Index: 1.458
• CAS DataBase Reference: N,N-DI-N-PROPYL-L-ALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-DI-N-PROPYL-L-ALANINE(81854-56-0)
• EPA Substance Registry System: N,N-DI-N-PROPYL-L-ALANINE(81854-56-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 81854-56-0(Hazardous Substances Data)

Usage

General Description

N,N-Di-N-propyl-L-alanine is a chemical compound classified as an alanine derivative, which is a type of amino acid. It is a chiral compound with two propyl substituents attached to the nitrogen atom of the alanine molecule. This chemical is not commonly found in nature but can be synthesized in the laboratory. It may have potential applications in pharmaceuticals, particularly in the development of new drugs, due to its unique structure and properties. However, further research is needed to fully understand the potential uses and effects of N,N-Di-N-propyl-L-alanine.

InChI:InChI=1/C9H19NO2/c1-4-6-10(7-5-2)8(3)9(11)12/h8H,4-7H2,1-3H3,(H,11,12)/t8-/m0/s1

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.